NASDAQ:MNKD
MannKind Corporation Stock News
$4.39
+0.0100 (+0.228%)
At Close: May 03, 2024
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
02:16pm, Wednesday, 25'th May 2022 Zacks Investment Research
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
10:00am, Tuesday, 24'th May 2022 GlobeNewswire Inc.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeuti
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
10:00am, Thursday, 19'th May 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p
Best Penny Stocks To Buy? 3 With Unusual Options Activity Today
01:31pm, Wednesday, 18'th May 2022
Penny stocks to watch with unusual options volume today. The post Best Penny Stocks To Buy?
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
10:06am, Tuesday, 17'th May 2022 GlobeNewswire Inc.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products
MannKind Corporation Participating at Upcoming Conferences
10:00am, Monday, 09'th May 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p
MannKind Corporation Participating at Upcoming Conferences
06:00am, Monday, 09'th May 2022
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro
MannKind Corporation (MNKD) Q1 2022 Earnings Call Transcript
05:30am, Friday, 06'th May 2022 The Motley Fool
MNKD earnings call for the period ending March 31, 2022.
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Thursday, 05'th May 2022 Zacks Investment Research
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation (MNKD) CEO Michael Castagna on Q1 2022 Results - Earnings Call Transcript
08:14pm, Thursday, 05'th May 2022
MannKind Corporation (NASDAQ:MNKD ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Michael Castagna – Chief Executive Officer Steven Binder – Chief Financial Officer
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Thursday, 05'th May 2022
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
10:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
10:00am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
06:00am, Thursday, 28'th Apr 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
02:35pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
